Published in Breast Cancer Res Treat on February 26, 2015
The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective. Breast Cancer Res Treat (2015) 0.83
A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana. BMC Clin Pathol (2015) 0.80
Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients. Curr Oncol (2016) 0.78
High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients. BMC Cancer (2016) 0.77
Genomic Disparities in Breast Cancer Among Latinas. Cancer Control (2016) 0.76
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79
Chromosomal region of the cystic fibrosis gene in yeast artificial chromosomes: a model for human genome mapping. Science (1990) 2.92
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res (2011) 2.64
Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ (2014) 2.60
Introduction of a normal human chromosome 11 into a Wilms' tumor cell line controls its tumorigenic expression. Science (1987) 2.52
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol (2014) 2.25
BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer (2009) 2.21
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer (2009) 2.01
Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev (2005) 2.00
Breast cancer genetics in African Americans. Cancer (2003) 1.65
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat (2003) 1.54
Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer (2011) 1.53
The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat (2001) 1.36
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat (2014) 1.35
High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat (2006) 1.34
Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol (2012) 1.28
Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol (2013) 1.26
Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev (2007) 1.25
Breast cancer in Mexico: a pressing priority. Reprod Health Matters (2008) 1.20
Breast cancer in Mexico: a growing challenge to health and the health system. Lancet Oncol (2012) 1.19
Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat (2006) 1.14
[Available resources for the treatment of breast cancer in Mexico]. Salud Publica Mex (2009) 1.08
A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast Cancer Res Treat (2010) 1.04
BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol (2007) 1.03
Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer. Clin Chem (2006) 1.03
BRCA1 and BRCA2 mutations in a South American population. Cancer Genet Cytogenet (2006) 0.98
Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer (2014) 0.97
First breast cancer mammography screening program in Mexico: initial results 2005-2006. Breast J (2009) 0.97
Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families. Breast Cancer Res Treat (2010) 0.93
Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations. Breast Cancer Res Treat (2005) 0.93
BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin. Springerplus (2012) 0.92
Frequency of germ-line BRCA1 mutations among Spanish families from a Mediterranean area. Hum Mutat (2000) 0.87
Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer. PLoS One (2012) 0.87
BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants. Breast Cancer Res Treat (2010) 0.86
Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients. Eur J Gynaecol Oncol (2009) 0.86
BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela. Biol Res (2012) 0.86
Screening for BRCA1 and BRCA2 mutations in breast cancer patients from Mexico: the public health perspective. Salud Publica Mex (2009) 0.86
Clinical follow up of mexican women with early onset of breast cancer and mutations in the BRCA1 and BRCA2 genes. Salud Publica Mex (2005) 0.85
BRCA2 mutation analysis of 87 Spanish breast/ovarian cancer families. Ann Oncol (2001) 0.84
Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia. Hered Cancer Clin Pract (2014) 0.84
Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. Clin Genet (2014) 0.83
BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica. Clin Genet (2011) 0.83
Molecular analysis of the eighteen most frequent mutations in the BRCA1 gene in 63 Chilean breast cancer families. Biol Res (2004) 0.82
Recurrent BRCA1 and BRCA2 mutations in Mexican women with breast cancer. Cancer Epidemiol Biomarkers Prev (2014) 0.78
Breast cancer in young women in Latin America: an unmet, growing burden. Oncologist (2013) 0.77
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet (2001) 5.08
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet (1996) 3.56
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst (1999) 3.26
CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet (2004) 3.03
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet (2000) 2.77
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer (2007) 2.62
Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol (2001) 2.41
Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med (2000) 2.39
Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet (1999) 2.36
Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer (1996) 2.33
Evidence-based cognitive rehabilitation: recommendations for clinical practice. Arch Phys Med Rehabil (2000) 2.33
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst (1998) 2.33
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet (2000) 2.31
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat (2008) 2.27
Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet (1997) 2.15
The impact of family history on early detection of prostate cancer. Nat Med (1995) 2.14
Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet (1999) 2.14
BRCA1 and BRCA2 mutations and the risk for colorectal cancer. Clin Genet (2014) 2.02
A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol (2001) 2.01
Voltage-sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current. Proc Natl Acad Sci U S A (2000) 1.97
On being the right size: a reappraisal of mammography trials in Canada and Sweden. Lancet (1997) 1.94
DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study. Arch Intern Med (1993) 1.91
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet (1998) 1.88
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res (2001) 1.81
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79
The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet (2002) 1.77
Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet (2005) 1.71
A breast-ovarian cancer susceptibility gene maps to chromosome 17q21. Am J Hum Genet (1993) 1.66
1H-MRS alterations in the cerebellum of patients with familial hemiplegic migraine type 1. Neurology (2005) 1.65
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61
Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res (2000) 1.57
Non-random transmission of mutant alleles to female offspring of BRCA1 carriers in Poland. J Med Genet (2003) 1.57
Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet (1997) 1.55
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology (2001) 1.54
In-situ breast cancer and BRCA1. Lancet (1996) 1.52
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2011) 1.51
Induction of systemic acquired disease resistance in plants by chemicals. Annu Rev Phytopathol (1994) 1.46
A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet (1996) 1.45
Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial. Ann Intern Med (1994) 1.45
Oat-cell carcinoma of the prostate. Diagnosis, prognosis and therapeutic implications. Urol Int (2001) 1.44
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat (2007) 1.44
Type III radical hysterectomy after induction chemotherapy for patients with locally advanced cervical carcinoma. Int J Gynecol Cancer (2001) 1.43
Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet (1997) 1.42
Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat (2005) 1.41
Fake Journals: Their Features and Some Viable Ways to Distinguishing Them. Sci Eng Ethics (2014) 1.39
Spinocerebellar ataxia type 6: evidence for a strong founder effect among German families. Neurology (1999) 1.39
Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev (2001) 1.35
Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab (2001) 1.35
Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet (1998) 1.35
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat (2014) 1.35
Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2004) 1.34
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2012) 1.34
BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat (2006) 1.33
Provider-patient communication and metabolic control. Diabetes Care (1993) 1.33
High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst (1994) 1.33
Screening for multiple endocrine neoplasia type 2a with DNA-polymorphism analysis. N Engl J Med (1989) 1.32
Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res (1997) 1.32
Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12-q21. Nat Genet (1996) 1.30
The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol (2011) 1.29
Family history and the risk of gastric cancer. Br J Cancer (2009) 1.27
Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol (2000) 1.26
NBS1 is a prostate cancer susceptibility gene. Cancer Res (2004) 1.24
A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet (2006) 1.24
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol (2000) 1.23
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics (2001) 1.23
Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab (2001) 1.22
A common variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet (2005) 1.22
Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br J Cancer (2008) 1.22
Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation. Clin Genet (2007) 1.21
Modification of uricaemia and the excretion of uric acid nitrogen by an enzyme of fungal origin. Nature (1968) 1.21
Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol (2002) 1.21
Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study. BMJ (1996) 1.20
Neuronal activity of the human subthalamic nucleus in the parkinsonian and nonparkinsonian state. J Neurophysiol (2008) 1.20
HPC2 variants and screen-detected prostate cancer. Am J Hum Genet (2001) 1.20
Variability of familial hemiplegic migraine with novel A1A2 Na+/K+-ATPase variants. Neurology (2004) 1.17
Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: evaluation of active electrode contacts. J Neurol Neurosurg Psychiatry (2003) 1.17
The contribution of founder mutations to early-onset breast cancer in French-Canadian women. Clin Genet (2009) 1.17
Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol (2000) 1.16
Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer (2012) 1.15
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene (2011) 1.12
In vitro antibacterial activity of trimethoprim alone and combined with sulfonamides. Antimicrob Agents Chemother (Bethesda) (1966) 1.12
Dichlorodiphenyltrichloroethane serum levels and breast cancer risk: a case-control study from Mexico. Cancer Res (1997) 1.12
An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer. Cancer Genet Cytogenet (1999) 1.12
Expression of ryanodine receptor RyR3 produces Ca2+ sparks in dyspedic myotubes. J Physiol (2000) 1.10
A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation. Ann Oncol (2003) 1.10
Secretory carcinoma of the breast containing the ETV6-NTRK3 fusion gene in a male: case report and review of the literature. World J Surg Oncol (2005) 1.08
Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling. Am J Hum Genet (2000) 1.07
The genetic basis of Muir-Torre syndrome includes the hMLH1 locus. Am J Hum Genet (1996) 1.07
A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes. Clin Genet (2000) 1.07
Deep brain stimulation in the subthalamic area is more effective than nucleus ventralis intermedius stimulation for bilateral intention tremor. Acta Neurochir (Wien) (2007) 1.06
Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol (2000) 1.06
Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Res Treat (2006) 1.05
Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress. Clin Genet (2013) 1.05